Financial Performance - Yalla Group achieved revenues of US$846 million in 2Q2025, compared to US$812 million in 2Q2024[34, 55] - Net income for 2Q2025 was US$365 million, representing a net margin of 432%[12, 34] - Average Monthly Active Users (MAUs) increased to 42421 thousand in 2Q2025, an 88% year-over-year growth[36] - The company maintains a strong cash flow position, with cash and cash equivalents, restricted cash, term deposits, and short-term investments totaling US$7041 million as of June 2025[53] Operational Efficiency - Cost of revenues decreased to US$279 million in 2Q2025, representing 330% of total revenues[38] - Selling and marketing expenses remained stable at US$87 million, accounting for 102% of total revenues[40] - General and administrative expenses increased to US$90 million, representing 106% of total revenues[43] - Technology and product development expenses increased to US$83 million, accounting for 99% of total revenues[46] Strategic Initiatives - The company repurchased 6230299 ADSs for approximately US$41 million in 1H2025 and is committed to repurchasing US$50 million for the full year[27] - All shares repurchased in 2025, totaling 6230299 ADSs, have been canceled[28]

For personal use only Gentrack Group CCG Boston 2025 12 Aug 2025 [NZX/ASX: GTK] © Gentrack 2025. All rights reserved. This document is the intellectual property of Gentrack. LEGAL NOTICE This presentation is provided by Gentrack Group Limited (NZCN 3768390) (Gentrack) to provide summary information about Gentrack and its subsidiaries (the Group). Statements in this presentation are made only as at 12 August 2025 and the information in this presentation remains subject to change without notice. The informati ...

Financial Highlights - FibroGen China sale预计总对价约为2.1亿美元，比最初的指导增加了5000万美元[3] - 通过出售FibroGen China，公司预计可以获得约1.25亿美元的净现金，并将现金流延长至2028年[3] - 公司将偿还Morgan Stanley Tactical Value定期贷款[3] FG-3246 & FG-3180 Program - FG-3246在既往接受大量治疗的转移性去势抵抗性前列腺癌(mCRPC)患者的1期单药治疗研究中，显示出有意义的临床活性，中位rPFS为8.7个月[14, 17] - 在FG-3246联合恩杂鲁胺治疗mCRPC的1b期研究中，观察到有临床意义的疗效信号，初步估计的中位rPFS为10.2个月，71%的可评估患者PSA下降[19] - FG-3246的2期单药治疗试验预计将于2025年第三季度启动，中期结果预计在2026年下半年公布[3, 38] Roxadustat - 在MATTERHORN 3期试验的事后亚组分析中，对于高输血负担的患者，Roxadustat与安慰剂相比显示出输血独立(TI)的益处，在28周内，Roxadustat组有36%的患者达到8周RBC-TI，而安慰剂组只有7%[49, 50] - 计划的关键性3期试验的最终方案预计将于2025年第四季度提交[3, 52]

Second Quarter 2025 Earnings Call August 11, 2025 Cautionary Statement Regarding Forward-looking Statements Pursuant to Safe Harbor Provisions of The Private Securities Litigation Reform Act of 1995 Cautionary Statement Regarding Forward-Looking Statements This presentation includes "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning Kodak's plans, objectives, goals, strategies, future event ...

Financial Performance - Q2 2025 revenue reached $91.3 million, a 9.2% year-over-year increase[18] - Q2 2025 gross margin improved to 34.7%, a 2.2 percentage point increase year-over-year[18] - Adjusted EBITDA for Q2 2025 was $25.9 million[20] - The company achieved an adjusted net profit of $16.3 million for the quarter after accounting for non-cash items[57] Regional Revenue - APAC revenue for Q2 2025 was $47.658 million, a 34% increase year-over-year[60] - EMEA revenue for Q2 2025 was $38.885 million, a 17% decrease year-over-year[60] - USA revenue for Q2 2025 was $4.796 million, a 276% increase year-over-year[60] Cash Flow and Outlook - The company ended the period with $138.8 million in cash, including restricted cash, a $29.2 million increase[66] - The company is targeting revenue growth of 18-25% for 2025[70] - Revenue guidance for 2025 is $450-475 million[71] - The company is targeting a gross margin of 30-32% for 2025[72]

Financial Highlights - Revenue increased by 18% year-over-year to $779 million in Q2 2025 [4, 8, 10] - Contribution ex-TAC increased by 16% year-over-year to $48 million in Q2 2025 [4, 8, 10] - Adjusted EBITDA increased by 18% year-over-year to $113 million in Q2 2025 [4, 12, 14] - Adjusted EBITDA margin was 23% of contribution ex-TAC in Q2 2025, flat year-over-year [4, 6, 14, 15] Growth Drivers - CTV represented nearly 45% of total advertiser spend in Q2 2025 [5] - Advertiser spend linked to Household ID increased 15% year-over-year [5] - The company established a growth pipeline of over $250 million in potential annualized ad spend opportunities [5] Stock Repurchase and Valuation - The company purchased 38 million shares of Class A common stock for a total of $502 million from May 1, 2024, through August 8, 2025, including $285 million year-to-date through August 8, 2025 [5, 19] - As of June 30, 2025, the company had a healthy cash & cash equivalents balance of $173 million and no debt outstanding [5] Q3 2025 Guidance - The company projects revenue between $835 million and $865 million, representing a 6% year-over-year increase at the midpoint [16] - The company projects contribution ex-TAC between $510 million and $530 million, representing a 10% year-over-year increase at the midpoint [16]

Financial Performance & Metrics - ZipRecruiter's Q1 2025 revenue reached $110.1 million[12] - The Adjusted EBITDA for Q1 2025 was $5.9 million, representing a 5% margin[12] - Revenue per Paid Employer in Q1 2025 was $1,734[12] - The company achieved a healthy 16% Adjusted EBITDA margin for FY 2024[15] Market Position & Growth - ZipRecruiter operates within a large Total Addressable Market (TAM) exceeding $300 billion in the recruiting industry[15, 16, 64, 65] - The company has amassed over 4 million businesses and over 170 million job seekers on its platform since its founding[15, 21] - ZipRecruiter delivered over 40 million "Great Match" candidates in 2024[15, 23] - ZipRecruiter has achieved 80% aided brand awareness among U S employers and job seekers[15, 42] - Online recruiting is growing faster (4 6% CAGR from 2020-2029) than the overall recruiting market (3 2% CAGR from 2020-2029)[69] Business Model & Technology - 78% of ZipRecruiter's revenue comes from flat-rate pricing (subscription plans), while 22% comes from performance-based pricing (cost-per-click)[26, 29] - 80% of employers using ZipRecruiter receive a quality candidate within the first 24 hours[23]

Financial Performance - Q4 revenue increased by 9.9% year-over-year to $273 million[5] - Full-year revenue increased by 9.2% year-over-year to $912 million[5] - Q4 Adjusted EBITDA increased to $51 million with a margin of 18.8%[5] - Full-year Adjusted EBITDA increased to $119 million with a margin of 13.1%[5] - Full-year free cash flow reached a record of $119 million[5] Bookings and Backlog - Record quarterly bookings of $342 million, resulting in a book-to-bill ratio of 1.25[5] - Record backlog of $1.4 billion[7] - Full-year book-to-bill ratio of 1.13[7] Margin Expansion - Q4 gross margin increased by 160 basis points year-over-year to 31%[8] - Expect fiscal year 2026 full-year adjusted EBITDA margin approaching mid-teens[10] Cash Flow and Debt - Net working capital is down $90 million year-over-year[5] - Net working capital is down $211 million from peak net working capital levels in Q1 of FY24[9] - Net debt decreased to $282 million, the lowest level since Q1 of FY22[9] FY26 Expectations - Expect full year fiscal 2026 revenue growth of low single-digits[10] - Expect to be free cash flow positive in fiscal 2026[10]

Financial Performance - Q2 2025 - Revenue increased by 1% year-over-year, from $74.9 million in Q2 2024 to $75.6 million in Q2 2025 [13] - Gross profit decreased by 2% year-over-year, from $58.6 million in Q2 2024 to $57.2 million in Q2 2025 [13] - Adjusted EBITDA decreased by 6% year-over-year, from $33.7 million in Q2 2024 to $31.8 million in Q2 2025 [13] - Free cash flow increased by 17% year-over-year, from $19.3 million in Q2 2024 to $22.6 million in Q2 2025 [13] - Free Cash Flow conversion increased from 57% to 71% [13] Segment Performance - Consumer Payments revenue increased by 2% year-over-year, from $69.3 million in Q2 2024 to $70.5 million in Q2 2025 [18] - Business Payments revenue increased by 9% year-over-year excluding political media, but decreased by 3% as reported [21] Liquidity and Debt - Total liquidity was $413 million as of June 30, 2025 [25, 49] - Net leverage ratio was 2.5x as of June 30, 2025, with net debt of $345 million and LTM Adjusted EBITDA of $137 million [27] Outlook - The company reiterates its previously provided financial outlook and expects sequential quarterly acceleration in normalized growth year-over-year [32]

Financial Performance - Q2 2025 revenue was $47.4 million[21] - Nucleic Acid Production (NAP) revenue was $31.1 million, representing 66% of total revenue[37] - Biologics Safety Testing (BST) revenue was $16.3 million, accounting for 34% of total revenue[37] - The company reported a GAAP net loss of $69.8 million, which includes a $30.4 million non-cash goodwill impairment charge[27] - Adjusted EBITDA was negative $10.4 million, with an adjusted EBITDA margin of -22%[27] - Basic and Diluted EPS were both negative $0.27, while Adjusted EPS was negative $0.08[29] Balance Sheet and Cash Flow - Cash used in operations during Q2 2025 was $10.3 million[33] - The company's cash position is $270 million, with long-term gross debt of $297 million, resulting in net cash of negative $27 million[33] Strategic Initiatives - A restructuring plan is in place, targeting more than $50 million in annual cost savings[15, 39] - The company aims to return to positive adjusted EBITDA in the second half of 2026[15] - The company is targeting positive free cash flow in the second half of 2026[15]